Diaceutics PLC (LON:DXRX - Get Free Report)'s share price shot up 1.4% during trading on Wednesday . The stock traded as high as GBX 142 ($1.91) and last traded at GBX 142 ($1.91). 84,904 shares changed hands during trading, a decline of 43% from the average session volume of 148,539 shares. The stock had previously closed at GBX 140 ($1.88).
Analyst Ratings Changes
Several analysts have recently commented on DXRX shares. Canaccord Genuity Group reaffirmed a "buy" rating and set a GBX 180 price objective on shares of Diaceutics in a research report on Tuesday, July 22nd. Royal Bank Of Canada reduced their price target on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating for the company in a report on Thursday, July 10th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Diaceutics presently has a consensus rating of "Buy" and a consensus target price of GBX 175.
Check Out Our Latest Stock Analysis on Diaceutics
Diaceutics Price Performance
The firm has a market cap of £120.06 million, a price-to-earnings ratio of -7,029.70 and a beta of 0.58. The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The business has a 50 day simple moving average of GBX 130.22 and a 200-day simple moving average of GBX 127.60.
About Diaceutics
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
